Development of a multivalent paediatric human vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR)

Vaccine

Volumn 32, Issue 18, 2014, Pages 2020-2021

  Fooks, Anthony R ^a,b   Koraka, Penelope ^c   de Swart, Rik L ^c   Rupprecht, Charles E ^d,e   Osterhaus, Albert D M E ^c  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ROSS UNIVERSITY SCHOOL OF VETERINARY MEDICINE   (Saint Kitts and Nevis)

^e Erasmus Forum A434   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RABIES VACCINE;

ACTIVE IMMUNIZATION; CHILDHOOD; DISEASE CARRIER; ENCEPHALITIS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MEASLES; MUMPS; NONHUMAN; NOTE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; RUBELLA; VACCINATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; RABIES; RABIES VACCINES; VACCINES, COMBINED;

EID: 84896547062     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.065     Document Type: Note

References (12)

1. World Health Organization Expert Consultation on Rabies WHO technical report series 982 (2nd report) 2013, 1-139. Geneva, Switzerland.
2. Hemachudha T., Ugolini G., Wacharapluesadee S., Sungkarat W., Shuangshoti S., Laothamatas J. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol 2013, 12(5):498-513.
3. Both L., Banyard A., van Dolleweerd C., Horton D., Ma J.K.C., Fooks A.R. Passive immunity in the prevention of rabies: a neglected tool for a neglected disease. Lancet Infect Dis 2012, 12(5):397-407.
4. Chulasugandha P., Khawplod P., Havanond P., Wilde H. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 2006, 24:1478-1482.
5. Malerczyk C., Vakil H.B., Bender W. Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV). Hum Vaccin Immunother 2013, 9(7):1454-1459.
6. Mallewa M., Fooks A.R., Banda D., Chikungwa P., Mankhambo L., Molyneux E., et al. Rabies encephalitis in a malaria-endemic area of Malawi, Africa. Emerg Infect Dis 2007, 13(1):136-139.
7. Monath T.P. Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine 2013, 31(46):5321-5338.
8. Lang J., Duong G.H., Nguyen V.G., Le T.T., Nguyen C.V., Kesmedjian V., et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 1997, 349(9066):1663-1665.
9. Gilbert A.T., Petersen B.W., Recuenco S., Niezgoda M., Gómez J., Laguna-Torres V.A., et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am J Trop Med Hyg 2012, 87(2):206-215.
10. Lievano F., Galea S.A., Thornton M., Wiedmann R.T., Manoff S.B., Tran T.N., et al. Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience. Vaccine 2012, 30(48):6918-6926.
11. Bechini A., Tiscione E., Boccalini S., Levi M., Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine 2012, 30(35):5179-5190.
12. Bengtsson K.L., Karlsson K.H., Magnusson S.E., Reimer J.M., Stertman L. Matrix-M adjuvant: enhancing immune responses by 'setting the stage' for the antigen. Expert Rev Vaccines 2013, 12(8):821-823.